Effects of glycosylation on heparin binding and antithrombin activation by heparin

Proteins: Structure, Function and Bioinformatics

Volumn 79, Issue 9, 2011, Pages 2735-2745

  Pol Fachin, Laercio ^a   Franco Becker, Camila ^a   Almeida Guimarães, Jorge ^a   Verli, Hugo ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Glycan; Glycosaminoglycan; Intermediate; Serpin; Transmission pathway

Indexed keywords

AMINO ACID; ANTITHROMBIN; GLYCAN; HEPARIN; OLIGOSACCHARIDE; SERINE PROTEINASE INHIBITOR;

ARTICLE; BINDING AFFINITY; DYNAMICS; GLYCOSYLATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE;

ANTITHROMBIN III; ASPARAGINE; BINDING SITES; CARBOHYDRATE CONFORMATION; CRYSTALLOGRAPHY, X-RAY; GLYCOSYLATION; HEPARIN; HUMANS; MOLECULAR DYNAMICS SIMULATION; PLIABILITY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ISOFORMS;

EID: 80051556888     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.23102     Document Type: Article

References (70)

1. Rau JC, Beaulieu LM, Huntington JA, Church FC. Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 2007; 5: 102-115.
2. Gettins PGW. Serpin structure, mechanism, and function. Chem Rev 2002; 102: 4751-4803.
3. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923-926.
4. Olson ST, Richard B, Izaguirre G, Schedin-Weiss S, Gettins PGW. Molecular mechanisms of antithrombineheparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. Biochimie 2010; 92: 1587-1596.
5. Olson ST, Swanson R, Raub-Segall E, Bedsted T, Sadri M, Petitou M, Herault J-P, Herbert J-M, Björk I. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin Thromb Haemost 2004; 92: 929-939.
6. Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. J Biol Chem 1992; 267: 12528-12538.
7. Peterson CB, Blackburn MN. Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding. J Biol Chem 1985; 260: 610-615.
8. Turko IV, Fan B, Gettins PGW. Carbohydrate isoforms of antithrombin variant N135Q with different heparin affinities. FEBS Lett 1993; 335: 9-12.
9. Brennan SO, George PM, Jordan RE. Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135. FEBS Lett 1987; 219: 431-436.
10. Picard V, Ersdal-Badju E, Bock SC. Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the β-antithrombin III isoform with enhanced heparin affinity. Biochemistry 1995; 34: 8433-8440.
11. Franzén LE, Svensson S, Larm O. Structural studies on the carbohydrate portion of human antithrombin III. J Biol Chem 1980; 255: 5090-5093.
12. Plematl A, Demelbauer UM, Josic D, Rizzi A. Determination of the site-specific and isoform-specific glycosylation in human plasma-derived antithrombin by IEF and capillary HPLC-ESI-MS/MS. Proteomics 2005; 5: 4025-4033.
13. Demelbauer UM, Plematl A, Josic D, Allmaier G, Rizzi A. On the variation of glycosylation in human plasma derived antithrombin. J Chromatogr A 2005; 1080: 15-21.
14. Turk B, Brieditis I, Bock SC, Olson ST, Björk I. The oligosaccharide side chain on Asn-135 of α-antithrombin, absent in β-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry 1997; 36: 6682-6691.
15. Witmer MR, Hatton MW. Antithrombin III-beta associates more readily than antithrombin III-alpha with uninjured and de-endothelialized aortic wall in vitro and in vivo. Arterioscler Thromb 1991; 11: 530-539.
16. Frebelius S, Isaksson S, Swedenborg J. Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform ATβ. Arterioscler Thromb Vasc Biol 1996; 16: 1292-1297.
17. Skinner R, Abrahams JP, Whisstock JC, Lesk AM, Carrell RW, Wardell MR. The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol 1997; 266: 601-609.
18. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997; 94: 14683-14688.
19. Whisstock JC, Pike RN, Jin L, Skinner R, Pei XY, Carrell RW, Lesk AM. Conformational changes in serpins. II. The mechanism of activation of antithrombin by heparin. J Mol Biol 2000; 301: 1287-1305.
20. Woods RJ. Computational carbohydrate chemistry: what theoretical methods can tell us. Glycoconj J 1998; 15: 209-216.
21. Zuegg J, Gready JE. Molecular dynamics simulation of human prion protein including both N-linked oligosaccharides and the GPI anchor. Glycobiology 2000; 10: 959-974.
22. Mandal TK, Mukhopadhyay C. Effect of glycosylation on structure and dynamics of MHC class I glycoprotein: a molecular dynamics study. Biopolymers 2001; 59: 11-23.
23. Pol-Fachin L, Fernandes CL, Verli H. GROMOS96 43a1 performance on the characterization of glycoprotein conformational ensembles through molecular dynamics simulations. Carbohydr Res 2009; 344: 491-500.
24. Verli H, Guimarães JA. Insights into the induced fit mechanism in antithrombin-heparin interaction using molecular dynamics simulations. J Mol Graph Model 2005; 24: 203-212.
25. IUPAC-IUBMB Commission on Biochemical Nomenclature. Nomenclature of carbohydrates. Pure Appl Chem 1996; 68: 1919-2008.
26. Schuettelkopf AW, van Aalten DMF. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 2004; 60: 1355-1363.
27. Schaftenaar G, Noordik JH. Molden: a pre- and post-processing program for molecular and electronic structures. J Comput Aided Mol Des 2000; 14: 123-134.
28. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996; 14: 33-38.
29. DeLano WL. The PyMOL molecular graphics system. San Carlos, CA: DeLano Scientific LCC; 2002.
30. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006; 22: 195-201.
31. van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: fast, flexible, and free. J Comput Chem 2005; 26: 1701-1718.
32. Scott WRP, Hünenberger PH, Tironi IG, Mark AE, Billeter SR, Fennen J, Torda AE, Huber T, Krueger P, van Gunsteren WF. The GROMOS biomolecular simulation program. J Phys Chem A 1999; 103: 3596-3607.
33. Verli H, Guimarães JA. Molecular dynamics simulation of a decasaccharide fragment of heparin in aqueous solution. Carbohydr Res 2004; 339: 281-290.
34. Becker CF, Guimarães JA, Verli H. Molecular dynamics and atomic charge calculations in the study of heparin conformation in aqueous solution. Carbohydr Res 2005; 340: 1499-1507.
35. McCoy AJ, Pei XY, Skinner R, Abrahams JP, Carrell RW. Structure of β-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity. J Mol Biol 2003; 326: 823-833.
36. Bohne-Lang A, von der Lieth C-W. Gly Prot: in silico glycosylation of proteins Nucleic Acids Res 2005; 33: W214-W219.
37. Fernandes CL, Sachett LG, Pol-Fachin L, Verli H. GROMOS96 43a1 performance in predicting oligosaccharide conformational ensembles within glycoproteins. Carbohydr Res 2010; 345: 663-671.
38. Pol-Fachin L, Verli H. Depiction of the forces participating in the 2-O-sulfo-α-L-iduronic acid conformational preference in heparin sequences in aqueous solutions. Carbohydr Res 2008; 343: 1435-1445.
39. Guerrini M, Guglieri S, Casu B, Torri G, Mourier P, Boudier C, Viskov C. Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for very high affinity induced by an unusual glucuronic acid residue. J Biol Chem 2008; 283: 26662-26675.
40. Richard B, Swanson R, Olson ST. The signature 3-O-sulfo group of the anticoagulant heparin sequence is critical for heparin binding to antithrombin but is not required for allosteric activation. J Biol Chem 2008; 284: 27054-27064.
41. Kusche M, Torri G, Casu B, Lindahl U. Biosynthesis of heparin. Availability of glucosaminyl 3-O-sulfation sites J Biol Chem 1990; 265: 7292-7300.
42. Berendsen HJC, Grigera JR, Straatsma TP. The missing term in effective pair potentials. J Phys Chem 1987; 91: 6269-6271.
43. de Groot BL, Grubmüller H. Water permeation across biological membranes: mechanism and dynamics of aquaporin-1 and GlpF. Science 2001; 294: 2353-2357.
44. Hess B, Bekker H, Berendsen HJC, Fraaije, JGEM. LINCS: a linear constraint solver for molecular simulations. J Comput Chem 1997; 18: 1463-1472.
45. Darden T, York D, Pedersen L. Particle mesh Ewald: an N-log(N) method for Ewald sums in large systems. J Chem Phys 1993; 98: 10089-10092.
46. Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys 1984; 81: 3684-3690.
47. Pol-Fachin L, Verli H. Molecular modeling on the characterization of glycoproteins conformation. In: Verli H, Guimarães JA, editors. Strategies for the determination of carbohydrates structure and conformation. Kerala, India: Transworld Research Network; 2010. pp 103-131.
48. Mulloy B, Forster MJ, Jones C, Davies DB. N.m.r. and molecular-modelling studies of the solution conformation of heparin. Biochem J 1993; 293: 849-858.
49. Khan S, Gor J, Mulloy B, Perkins SJ. Semi-rigid solution structures of heparin by constrained X-ray scattering modelling: new insight into heparin-protein complexes. J Mol Biol 2010; 395: 504-521.
50. Meagher JL, Olson ST, Gettins PGW. Critical role of the linker region between helix D and strand 2A in heparin activation of antithrombin. J Biol Chem 2000; 275: 2698-2704.
51. Johnson DJD, Huntington JA. Crystal structure of antithrombin in a heparin-bound intermediate state. Biochemistry 2003; 42: 8712-8719.
52. Johnson DJD, Langdown L, Li W, Luis SA, Baglin TA, Huntington JA. Crystal structure of monomeric native antithrombin reveals a novel reactive center loop conformation. J Biol Chem 2006; 281: 35478-35486.
53. Langdown L, Belzar KJ, Savory WJ, Baglin TA, Huntington JA. Thecritical role of hinge-region expulsion in the induced-fit heparin binding mechanism of antithrombin. J Mol Biol 2009; 386: 1278-1289.
54. Karplus M, McCammon JA. Molecular dynamics simulations of biomolecules. Nat Struct Biol 2002; 9: 646-652.
55. Olson ST, Srinivasan KR, Björk I, Shore JD. Binding of high affinity heparin to antithrombin III. Stopped flow kinetic studies of the binding interaction. J Biol Chem 1981; 256: 11073-11079.
56. Schedin-Weiss S, Richard B, Olson ST. Kinetic evidence that allosteric activation of antithrombin by heparin is mediated by two sequential conformational changes. Arch Biochem Biophys 2010; 504: 169-176.
57. Ersdal-Badju E, Lu A, Zuo Y, Picard V, Bock SC. Identification of the antithrombin III heparin binding site. J Biol Chem 1997; 272: 19393-19400.
58. Desai U, Swanson R, Bock SC, Björk I, Olson ST. Role of arginine 129 in heparin binding and activation of antithrombin. J Biol Chem 2000; 275: 18976-18984.
59. Arocas V, Turk B, Bock SC, Olson ST, Björk I. The region of antithrombin interacting with full-length heparin chains outside the high-affinity pentasaccharide sequence extends to Lys136 but not to Lys139. Biochemistry 2000; 39: 8512-8518.
60. Arocas V, Bock SC, Raja S, Olson ST, Björk I. Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding. J Biol Chem 2001; 276: 43809-43817.
61. Schedin-Weiss S, Desai UR, Bock SC, Gettins PGW, Olson ST, Björk I. Importance of lysine 125 for heparin binding and activation of antithrombin. Biochemistry 2002; 41: 4779-4788.
62. Jairajpuri MA, Lu A, Desai UR, Olson ST, Björk I, Bock SC. Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation. J Biol Chem 2003; 278: 15941-15950.
63. Garone L, Edmunds T, Hanson E, Bernasconi R, Huntington JA, Meagher JL, Fan B, Gettins PGW. Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155. Biochemistry 1996; 35: 8881-8889.
64. Olson ST, Frances-Chmura AM, Swanson R, Björk I.Zettlmeissl G. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity Arch Biochem Biophys 1997; 341: 212-221.
65. Björk I, Ylinenjärvi K, Olson ST, Hermentin P, Conradt HS, Zettlmeissl G. Decreased affinity of recombinant antithrombin for heparin due to increased glycosylation. Biochem J 1992; 286: 793-800.
66. Belzar KJ, Zhou A, Carrell RW, Gettins PGW, Huntington JA. Helix D elongation and allosteric activation of antithrombin. J Biol Chem 2002; 277: 8551-8558.
67. Langdown J, Johnson DJ, Baglin TP, Huntington JA. Allosteric activation of antithrombin critically depends upon hinge region extension. J Biol Chem 2004; 279: 47288-47297.
68. Van Boeckel CAA, Grootenhuis PDJ, Visser A. A mechanism for heparin-induced potentiation of antithrombin III. Nat Struct Biol 1994; 1: 423-425.
69. Huntington JA, McCoy A, Belzar KJ, Pei XY, Gettins PGW, Carrell RW. The conformational activation of antithrombin. A 285-Å structure of a fluorescein derivative reveals an electrostatic link between the hinge and heparin binding regions J Biol Chem 2000; 275: 15377-15383.
70. dela Cruz RG, Jairajpuri MA, Bock SC. Disruption of a tight cluster surrounding tyrosine 131 in the native conformation of antithrombin III activates it for factor Xa inhibition. J Biol Chem 2006; 281: 31668-31676.